Published in

Massachusetts Medical Society, New England Journal of Medicine, 24(365), p. 2268-2276

DOI: 10.1056/nejmoa1109867

Links

Tools

Export citation

Search in Google Scholar

Dronedarone in high-risk permanent atrial fibrillation.

Journal article published in 2011 by R. Zimlichman, F. J. de Looze, W. J. van Gaal, A. A. de Paola, W. K. de Souza, S. L. Zimmermann ORCID, F. de Tommasi, G. J. de Weerd, F. R. den Hartog, R. van der Heijden, M. W. van Hessen, S. K. Zoet-Nugteren, K. N. Zrazhevskiy, Stuart J. Connolly, S.-A. Chen and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Orange circle
Published version: archiving restricted
Data provided by SHERPA/RoMEO

Abstract

Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients. (Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.).